- Home
- CRBP vs ORBS Comparison
CRBP vs ORBS Comparison
Compare CRBP & ORBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRBP | ORBS |
|---|---|---|
| Founded | 2009 | 1966 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.4M | 161.8M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRBP | ORBS |
|---|---|---|
| Price | $11.46 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | 290.4K | ★ 15.8M |
| Earning Date | 05-08-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $116.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $6.73 | $0.74 |
| 52 Week High | $20.56 | $15.96 |
Technical Indicators
Market Signals| Indicator | CRBP | ORBS |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 49.52 |
| Support Level | $9.32 | $0.77 |
| Resistance Level | $11.64 | $1.33 |
| Average True Range (ATR) | 0.70 | 0.07 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 91.59 | 67.30 |
Price Performance
Historical ComparisonAbout CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ORBS Eightco Holdings Inc.
Eightco Holdings Inc operates in Forever 8 Inventory Cash Flow Solution. The company is a dynamic technology-focused company committed to driving growth and innovation through strategic acquisitions and management. Forever 8 focuses on purchasing inventory for e-commerce retailers and is part of its Inventory Solution Business.